April 3, 2019 (Noon–1:15 p.m. ET)
Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), Best Pharmaceuticals for Children Act, NICHD
Pediatric obesity is associated with myriad medical, psychological, and neurocognitive abnormalities that affect children's health and quality of life. Because lifestyle interventions are not uniformly successful at reducing body weight and its complications in children or adolescents, there has been longstanding interest in the potential for pharmacotherapy to ameliorate pediatric obesity. In this lecture, presenter Jack A. Yanovski, M.D., Ph.D., will review the medications that are FDA-approved for obesity management, their mechanisms of action, the data for their efficacy in pediatric samples, and their side effect profiles. He also will:
- Describe the limited data supporting the use of anorexiant agents to treat childhood obesity.
- Describe the limited evidence supporting the use of malabsorptive agents to treat childhood obesity.
- Describe the limited data evidence supporting the use of therapies that diminish insulin secretion to treat childhood obesity.
- Explain the mechanisms of action of new agents approved for use in adults over the past year but not yet studied in pediatric samples.
Dr. Yanovski is chief of the section on growth and obesity in the program on developmental endocrinology and genetics at NICHD.
George Giacoia, OPPTB, NICHD